Esther Conde is a pathologist at “12 de Octubre” University Hospital in Madrid (Spain). She received her MD and PhD from Salamanca University (Salamanca) and Complutense University (Madrid), respectively, and completed her residency in pathology at the “12 de Octubre” University Hospital. Dra. Conde has also been a visiting researcher at the Lung Cancer Group in CNIO (Madrid). Her main clinical and research expertise is in cancer biomarker testing with a special emphasis in lung cancer.

Dr. Berezowska is an associate professor for pulmonary pathology at the University of Lausanne and a senior consultant pathologist at the Institute of Pathology of the Lausanne University Hospital (CHUV), Switzerland. She completed her residency at the Institutes of Pathology of the Ludwig Maximilians University in Munich (Germany) and University of Bern (Switzerland). In the following years as a full staff member at the Institute of Pathology of the University of Bern, she set her diagnostic and research focus on lung pathology, and consolidated her knowledge during a 3-months stay at the University of Michigan in Ann Arbor. Since 2014, she was in charge of thoracic pathology diagnostics and research in Bern, before moving to Lausanne.
Her research focuses on tissue based assessment of lung cancer including its brain metastases in the field of biomarker research, currently expanded by digital pathology approaches.
Dr. Berezowska is an active member of several international and national societies and serves currently as a member of the Pathology Committee of the IASLC.

Dr. Levy is Associate Professor at the Johns Hopkins School of Medicine and recently recruited to be Clinical Director of The Sidney Kimmel Cancer Center, Johns Hopkins Medicine at Sibley Hospital in Washington DC. Prior to his Hopkins appointment, Dr Levy was Medical Director of Thoracic Oncology Program for Mount Sinai Health Systems in New York City and Associate Director of the Cancer Clinical Trials Office (CCTO). Dr Levy is a physician scientist who is currently leading global immunotherapy trials evaluating checkpoint point inhibitors with novel combination strategies. In addition, he currently leads multiple targeted therapy trial with specific interest in EGFR mutations. Dr. Levy has played an integral role on several American Society of Clinical Oncology (ASCO) committees and currently serves as editor in chief for the ASCO Self Evaluation Program (SEP). He also serves on the Lungevity Scientific Advisory board as well as the IASLC’s International Lung Cancer Foundation Advisory Board. He is an ad hoc reviewer for Clinical Cancer Research (CCR), Annals of Oncology and the Journal of Clinical Oncology. He was recently selected as one of only 15 oncologist in the country to the prestigious ASCO Leadership Development Program whose mission is to identify and develop future leaders of ASCO.